Detection of aberrant methylation of 10 genes in genomic DNA of lung tumors
Authors:
Open Access
- 15 August 2013
- journal article
- letter
- Published by Elsevier in Annals of Oncology
- Vol. 24 (10) , 2705-2706
Abstract
Lung cancer is the leading cause of cancer-related death in most of the countries [1]. Two-thirds of patients have advanced stages of tumors at the time of diagnosis, which results high mortality among lung cancer patients [2]. Identification of cancer-specific markers could help to develop early diagnostic tests and to improve the survival rates substantially. Epigenetic changes, such as DNA methylation of CpG islands in the promoter of some tumor suppressor genes (TSGs), are frequently associated with ‘gene silencing’ [3]. Thus far, TSGs such as APC, p16, CDH1, RARβ-2, and RASSF1A have been found to have hypermethylated promoters in 30% of lung tumors [4, 5]. We have determined the frequency of promoter methylation of 10 TSGs (APC, SHP1, CDH1, SFRP1, Socs, GSTP1, P16, DLC1, DAPK, and RarB2) in surgically removed lung tumors. The tumor tissues were obtained from 30 lung cancer patients, who underwent curative surgery from 2009 to 2011 at Masih Daneshvari Hospital. The histological examination revealed that 24 of the 30 (80%) tumors were non-small-cell lung cancer (NSCLC), two (6.6%) were small-cell carcinoma (SCLC), and four (13.3%) other types. The median age of the patients was 50.66 (range: 25–75) years. The leukocyte DNA from 25 healthy individuals were used as control samples. The median age of the control population was 35.7 (range: 25–53) years. All DNAs were extracted using the QIAamp DNA mini Kit (QIAGENE cat. 51304) and were subjected to bisulfite treatment, using the Epitect Bisulfite Kit from Qiagen (Berlin, Germany). The bisulfite-modified DNA was used as a template for fluorescence-based real-time polymerase chain reaction (PCR). One of the healthy individual leukocytes were methylated in vitro with excess SssI methyltransferase (Zymoresearch, USA) to generate completely methylated DNA. The TSGs promoter methylation level in each sample was calculated and normalized with respect to the internal reference gene, β-actin. The percentage of methylation ratios (PMRs) represent the relative level of methylation in a particular sample: 100 × [(GENEX mean value) sample/(ACTB mean value) sample]/[(GENEX mean value) M.SssI/(ACTB mean value) M.SssI ] and were used for direct comparison of the samples. Cutoffs were set by receiver characteristic operator curves (ROCs). The Fisher's exact tests (two-sided) were carried out to detect significant methylation differences between the two groups. The pathological analysis revealed that most of the patients (80%) had NSCLC. SOCs, GSTP, and SHP1 genes were eliminated as possible cancer diagnostic markers, because SOCs and GSTP1 had no detectable promoter methylation in these cancer patients and SHP1 showed 100% methylation in both the experimental and control population. The methylation results of the remaining seven candidate genes are summarized in Table 1. Genes such as APC, CDH1, and DAPK were most frequently methylated when compared with controls, occurring in 23 (77%) versus 8% of control (P = 0.005) for APC, 18 (60%) versus 8% (P ≤ 0.001) for CDH1, and 12 (40%) versus 0% (P ≤ 0.0001) for DAPK. The other four genes were also significantly methylated, 27% (P = 0.005) for SFRP1, 20% (P = 0.005) for p16, 20% (P = 0.009) for DLC1, and 16% (P = 0.009) for RARβ2 gene. Only 2 of the 25 control (normal leukocytes) showed methylation for APC and another 2 for CDH1 gene. Age was no factor, but gender seems to be a factor at least in this set of patient population. Our data show that 7 of 13 female patients (54%) had one or no methylated gene, while 14 of 17 male patients (82%) had more than one gene methylated. Our data suggest that APC, CDH1, and DAPK could serve as lung cancer-specific panel for methylation detection and ultimately for diagnostic purposes. At least one gene from this panel was detected to be methylated at promoter region in 27 of the 30 lung cancer patients (sensitivity 90%) and only 4 of 25 control samples (specificity 84%).Keywords
Funding Information
- Tofigh Daru
This publication has 5 references indexed in Scilit:
- Aberrant DNA Methylation in Lung Cancer: Biological and Clinical ImplicationsThe Oncologist, 2002
- DNA methylation analysis: a powerful new tool for lung cancer diagnosisOncogene, 2002
- DNA methylation, nuclear structure, gene expression and cancerJournal of Cellular Biochemistry, 2000
- Global cancer statisticsCA: A Cancer Journal for Clinicians, 1999
- Prognosis and survival in resected lung carcinoma based on the new international staging systemThe Journal of Thoracic and Cardiovascular Surgery, 1988